. 2010 Jun 21;3:197–213. doi: 10.2147/dmsott.s7315

Table 2.

Studies conducted in patients with type 2 diabetes

Study (reference)	Comparator	Additional glucose-lowering treatment	Trial duration (weeks)	No. participants (ITT) in the insulin detemir group	Baseline HbA_1c (%)	Endpoint HbA_1c (%)	Mean weight change (kg)	Hypoglycemia (relative risk for detemir)		Mean endpoint SMFPG (mmol/L)	Within-patient SD in FPG (mmol/L)
					Comparator	Comparator	Comparator	24 hours	Nocturnal	Comparator	Comparator
Haak et al⁶³	NPH	Insulin aspart	26	341	7.9	7.6	+1.0	0.84	1.02	9.7	1.3
Haak et al⁶³	NPH	Insulin aspart	26	164	7.8	7.5	+1.8^*	0.84	1.02	9.6	1.4^*
^dPhilis-Tsimikas et al⁶⁵	NPH	OADs	20	165/169	9.08/8.88	7.50/7.40	+1.2/+0.7	0.68/0.47^*	0.13^**/0.35^	7.97/6.50	Not reported
^dPhilis-Tsimikas et al⁶⁵	NPH	OADs	20	164	9.15	7.35	+1.6^**	0.68/0.47^*	0.13^**/0.35^	6.78	Not reported
Hermansen et al⁶¹	NPH	OADs	24	227	8.6	6.8	1.2	0.53^***	0.45^***	6.9^a	0.88
Hermansen et al⁶¹	NPH	OADs	24	225	8.5	6.6	2.8^***	0.94	1.05	6.6^a	0.99^**
Rosenstock et al⁶⁶	Insulin glargine	OADs	52	291	8.64	7.16	+3.0			7.14^a	1.06
Rosenstock et al⁶⁶	Insulin glargine	OADs	52	291	8.62	7.12	+3.9^**			6.98^a	1.03
Hollander et al⁶⁷	Insulin glargine	Insulin aspart	52	214	8.6	7.19	+2.8	0.75	0.63/1.15 (OD/BID)	7.05	1.36
Hollander et al⁶⁷	Insulin glargine	Insulin aspart	52	105	8.8	7.03	+3.8^*	0.75	0.63/1.15 (OD/BID)	6.68	1.39

Notes: Study also compared detemir OD in the morning with detemir OD in the evening. Results from both are shown here;

P < 0.05;

^**

P < 0.01;

^***

P < 0.001.

Abbreviations: FPG, fasting plasma glucose; NPH, neutral protamine Hagedorn insulin; HbA_1c, glycosylated hemoglobin; ITT, intent to treat; OAD, oral antidiabetic; OD, once daily; BID, twice daily; SMFPG, self-measured fasting plasma glucose; SD, standard deviation.